{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-001049","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.985310+00:00","generated_at":"2026-05-26T16:08:43.866088+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ZEO ScientifiX appoints Dr. Peter A.M. Everts as Chief Scientific and Technology Officer","bullets":["Dr. Everts brings 35+ years of experience in orthobiology, spine, wound care, and regenerative medicine.","Previously CSO at EmCyte Corp and co-founder of Da Vinci Clinic, Netherlands; holds Ph.D. from University of Utrecht.","ZEO is a clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases.","Interim CEO Ian Bothwell says appointment underscores commitment to accelerating innovation and expanding regenerative therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-001049","json":"https://secwatch.observer/filing/0001829126-25-001049.json","markdown":"https://secwatch.observer/filing/0001829126-25-001049.md","text":"https://secwatch.observer/filing/0001829126-25-001049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625001049/0001829126-25-001049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625001049/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:08:43.866088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}